COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
COVID-19
autologous stem cell transplantation
myeloma
outcome
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
24
01
2023
received:
27
11
2022
accepted:
06
02
2023
medline:
11
8
2023
pubmed:
15
2
2023
entrez:
14
2
2023
Statut:
ppublish
Résumé
Here we report two cases of myeloma patients who became positive for SARS-CoV-2 infection during the acute phase of autologous stem cell transplant. Both patients were promptly treated with monoclonal antibodies and remdesivir, and, despite the profound neutropenia and lymphopenia, they did not develop respiratory failure and they remained paucisymptomatic during the entire period of aplasia. Neutrophil engraftment took place as expected and the patients were discharged quickly and did not experience adverse effects after discharge.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-558Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745. https://doi.org/10.1016/S2352-3026(20)30251-9
Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139(10):1588-1592. https://doi.org/10.1182/blood.2021014124
Cattaneo C, Masina L, Pagani C, et al. High mortality in fully vaccinated hematologic patients treated with anti-CD20 antibodies during the “Omicron wave” of COVID-19 pandemic. Hematol Oncol. 2022;41(1):205-207. Online ahead of print. https://doi.org/10.1002/hon.3064
Ljungman P, Mikulska M, de la Camara R, et al. The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transpl. 2020;55(11):2071-2076. https://doi.org/10.1038/s41409-020-0919-0
Malek AE, Adachi JA, Mulanovich VE, et al. Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients. Transpl Infect Dis. 2021;23(4):e13606. https://doi.org/10.1111/tid.13606
Milczarek S, Baumert B, Sobuś A, et al. COVID-19 during early phase of autologous stem cell transplantation. Medicina (Kaunas). 2021;57(7):724. https://doi.org/10.3390/medicina57070724
Teh JSK, Coussement J, Neoh ZCF, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022;6(7):2014-2034. https://doi.org/10.1182/bloodadvances.2021006333
Ullrich F, Hanoun C, Turki AT, et al. Early report on the severity of COVID-19 in hematologic patients infected with the SARS-CoV2 omicron variant. Eur J Haematol. 2022;109(4):364-372. https://doi.org/10.1111/ejh.13818
Jaroszewicz J, Kowalska J, Pawłowska M, et al. Remdesivir decreases mortality in COVID-19 patients with active malignancy. Cancers. 2022;14(19):4720. https://doi.org/10.3390/cancers14194720
Marasco V, Piciocchi A, Candoni A, et al. Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: the GIMEMA EMATO-0321 study. Br J Haematol. 2022;199(1):54-60. https://doi.org/10.1111/bjh.18385